Forthcoming Meetings

IF 2.4 Q2 CLINICAL NEUROLOGY Neuro-oncology practice Pub Date : 2023-01-13 DOI:10.1093/nop/npac096

引用次数: 0

Abstract

Journal Article Forthcoming Meetings Get access Neuro-Oncology Practice, Volume 10, Issue 1, February 2023, Page 108, https://doi.org/10.1093/nop/npac096 Published: 13 January 2023 Article history Corrected and typeset: 13 January 2023 Published: 13 January 2023

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

即将到来的会议

期刊文章即将召开的会议获取神经肿瘤学实践，第10卷，第1期，2023年2月，108页，https://doi.org/10.1093/nop/npac096出版:2023年1月13日文章历史更正和排版:2023年1月13日出版:2023年1月13日

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Neuro-oncology practice CLINICAL NEUROLOGY-

CiteScore

5.30

自引率

11.10%

发文量

期刊介绍： Neuro-Oncology Practice focuses on the clinical aspects of the subspecialty for practicing clinicians and healthcare specialists from a variety of disciplines including physicians, nurses, physical/occupational therapists, neuropsychologists, and palliative care specialists, who have focused their careers on clinical patient care and who want to apply the latest treatment advances to their practice. These include: Applying new trial results to improve standards of patient care Translating scientific advances such as tumor molecular profiling and advanced imaging into clinical treatment decision making and personalized brain tumor therapies Raising awareness of basic, translational and clinical research in areas of symptom management, survivorship, neurocognitive function, end of life issues and caregiving

期刊最新文献

Reviewer List for the year 2024. Should we be testing for germline and "actionable" mutations in all glioma patients? Foreword. Role of the tumor board when prescribing mutant isocitrate dehydrogenase inhibitors to patients with isocitrate dehydrogenase-mutant glioma. Financial challenges of being on long-term, high-cost medications.